peptidedosing.eu
Find a peptide
Weight & metabolism

Cagrilintide

An experimental appetite drug, tested together with semaglutide.

StatusInvestigational; not approved (EU/UK/US) as of Oct 2026
How well studied in peopleTested in clinical trials
Experts quoted1 expert

iNot medical advice. We don’t recommend any dose. Every dose below is a quote from the person named, describing their views or their own use. Cagrilintide is investigational. Neither cagrilintide nor CagriSema was approved in the US or EU as of 9 October 2026; Novo Nordisk has filed CagriSema with the FDA and expects a decision in Q4 2026. Products sold online are not the investigational drug.

What experts say about dosing

2 statements from 1 person. Each one is word for word: we add punctuation only and mark cuts with […]. The chips repeat the exact words used.

Vigorous SteveBodybuilding coach and YouTuber (VigorousSteve)

Own use with retatrutide (stopped)

Dose
“half a milligrams … three times a week”
How often
“three times a week”
How long
“after 3 weeks … out”
Also said
“combined with retatrutide”

“So I tried kagarinitide […] tried, um, I think at the time was four milligrams of rotoutide or 1 milligram rotoutide three times a week, so four milligrams a week or three milligrams a week, and then I added in half a milligrams ka linenotide three times a week. So it's 1.5 milligrams total, and I was so lethargic, dude, I was so tired, so I just ate more.”

Watch at 23:10BAM15 Vs. ATX-304, Cagrilintide Vs. Eloralintide… (VigorousSteve livestream) · 19 Jun 2026

Context: Solo livestream answering chat questions. The auto-captions garble the drug names: “kagarinitide” and “ka linenotide” are cagrilintide, “rotoutide” is retatrutide (flagged for a listen). The cut removes a mention of where the compounded product came from. A few seconds later he says: “after 3 weeks I was like you know what [ __ ] this ka linenide is out.”

Starting approach

Dose
“maybe 1 milligram to two milligrams”
Also said
“dose low and escalate your way up”

“I would do a dose low and and escalate your way up. It seems that people on a milligram for milligram basis compared to the GLP ones, they respond a lot more […] substantially. So you would maybe run 1 milligram to two milligrams of the amalin receptor agonists”

Watch at 24:45BAM15 Vs. ATX-304, Cagrilintide Vs. Eloralintide… (VigorousSteve livestream) · 19 Jun 2026

Context: Same livestream. He is speaking about amylin-receptor agonists in general (cagrilintide and eloralintide). He ends: “it's you know worth looking into but I didn't get a good response.” The cut removes a hesitation (“um um how do you say this?”).

What experts say about safety

0 statements from 0 people about risks and how strong the evidence is.

No expert safety statements are listed yet.

Go deeper

What the research used

Context, not a dosing guide. These are the doses used in Novo Nordisk’s trials, given under medical supervision with gradual dose escalation. They are listed as evidence context, not as a guide.

Cagrilintide alone

StudyStudied inWhat the study usedWhat it found
Lau et al., 2021, LancetPubMed 34798060706 adults with overweight or obesity (phase 2)Once-weekly cagrilintide 0.3–4.5 mg for 26 weeksWeight loss 6.0–10.8% vs 3.0% with placebo; 4.5 mg beat liraglutide 3.0 mg (10.8% vs 9.0%); mainly GI side effects

Cagrilintide with semaglutide (CagriSema)

StudyStudied inWhat the study usedWhat it found
Enebo et al., 2021, LancetPubMed 3389483896 adults (phase 1b)Cagrilintide 0.16–4.5 mg with semaglutide 2.4 mg, 20 weeksUp to 15.4% weight loss vs 8.0% with semaglutide plus placebo; acceptable safety
Frias et al., 2023, LancetPubMed 3736459092 adults with type 2 diabetes (phase 2)CagriSema 2.4/2.4 mg weekly, 32 weeksWeight change −15.6% (CagriSema) vs −5.1% (semaglutide) vs −8.1% (cagrilintide)
Garvey et al., 2025, N Engl J Med (REDEFINE 1)PubMed 405444333,417 adults with obesity or overweightCagriSema 2.4/2.4 mg weekly, 68 weeksWeight change −20.4% vs −3.0% with placebo; GI adverse events 79.6% vs 39.9%
Davies et al., 2025, N Engl J Med (REDEFINE 2)PubMed 405444321,206 adults with obesity and type 2 diabetesCagriSema 2.4/2.4 mg weekly, 68 weeksWeight change −13.7% vs −3.4% with placebo; GI adverse events 72.5% vs 34.4%
What we don’t know yet
  • Most large trials tested cagrilintide combined with semaglutide, not on its own.
  • Gastrointestinal side effects were common in every trial.
  • Long-term outcomes (beyond 68 weeks) are not yet published.
  • Online “research” cagrilintide is not the trial product; identity and purity are unknown.
Common questions

What is CagriSema?

A once-weekly combination of cagrilintide 2.4 mg and semaglutide 2.4 mg being developed by Novo Nordisk. It was under FDA review in October 2026.

Is cagrilintide approved?

Not as of 9 October 2026, either alone or as CagriSema.

What did Vigorous Steve report?

He says he stopped it after 3 weeks because he felt lethargic, and that he “didn't get a good response”. See his quotes.

Why does the protocol section only contain quotes?

We do not write our own dose ranges. The protocol cards show, word for word, what named people have publicly said, with their caveats and a link to the source.

About this page

Word-for-word statements about cagrilintide, a long-acting amylin analogue, each with a link to the source. The large clinical trials, mostly in combination with semaglutide (CagriSema), are listed separately as context.

Also known as
NN9838; component of CagriSema (with semaglutide)
Type
Long-acting amylin analogue (once-weekly injection)
Last updated
11 Oct 2026

Last reviewed 11 Oct 2026 · Compiled by the Peptide Dosing editorial team · How we check quotes